Gossamer Bio Announces Appointment of Faheem Hasnain as Chief Executive Officer
November 16 2020 - 7:01AM
Business Wire
Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage
biopharmaceutical company focused on discovering, acquiring,
developing and commercializing therapeutics in the disease areas of
immunology, inflammation and oncology, today announced that the
Company’s Board of Directors has appointed Faheem Hasnain as Chief
Executive Officer and President, effective immediately. Mr. Hasnain
is a Co-Founder, former Chief Executive Officer, and current
Chairman of Gossamer Bio. Mr. Hasnain succeeds Sheila Gujrathi,
M.D., a Co-Founder of Gossamer Bio, who served as Chief Executive
Officer and President since July 2018. Dr. Gujrathi will continue
in an advisory role to the Company.
“I would like to thank Sheila for her invaluable contributions
to Gossamer Bio, from the founding of the Company to the
significant progress we have made across our pipeline, and we wish
her best of luck as she moves on to new endeavors,” said Mr.
Hasnain. “I am extremely excited to lead the Gossamer Bio team as
we continue to advance our pipeline and work to develop important
new therapies with tremendous potential to benefit high unmet need
patient populations.”
“I am very grateful for having had the opportunity to build and
lead a world-class Gossamer Bio team. I am proud of what we have
achieved together advancing our innovative research and development
programs and look forward to the future success of the Company,”
said Dr. Gujrathi.
Prior to co-founding Gossamer Bio, Mr. Hasnain served as
President, CEO and as a Director of Receptos, Inc. from November
2010 to August 2015. Receptos was a public company formed in 2009
focused on developing treatments in immunology and metabolic
disorders and was purchased by Celgene Corporation in August 2015.
Previously, Mr. Hasnain was the President and Chief Executive
Officer and a director of Facet Biotech Corporation, a
biology-driven antibody company with a focus in multiple sclerosis
and oncology. He held that position from December 2008 until the
company's acquisition by Abbott Laboratories in April 2010.
About Gossamer Bio
Gossamer Bio is a clinical-stage biopharmaceutical company
focused on discovering, acquiring, developing and commercializing
therapeutics in the disease areas of immunology, inflammation and
oncology. Its goal is to be an industry leader in each of these
therapeutic areas and to enhance and extend the lives of patients
suffering from such diseases.
Forward-Looking Statements
Gossamer cautions you that statements contained in this press
release regarding matters that are not historical facts are
forward-looking statements. These statements are based on the
Company’s current beliefs and expectations. Such forward-looking
statements include, but are not limited to, statements regarding:
our plans to advance our development pipeline and the potential of
our product candidates to benefit high unmet need patient
populations. The inclusion of forward-looking statements should not
be regarded as a representation by Gossamer that any of its plans
will be achieved. Actual results may differ from those set forth in
this press release due to the risks and uncertainties inherent in
Gossamer’s business, including, without limitation: risks and
uncertainties related to management and key personnel changes;
potential delays in the commencement, enrollment and completion of
clinical trials; disruption to our operations from the COVID-19
pandemic, including clinical trial delays; the Company’s dependence
on third parties in connection with product manufacturing, research
and preclinical and clinical testing; the success of Gossamer’s
clinical trials and preclinical studies for its product candidates;
and other risks described in the Company’s prior press releases and
the Company’s filings with the Securities and Exchange Commission
(SEC), including under the heading “Risk Factors” in the Company’s
annual report on Form 10-K and any subsequent filings with the SEC.
You are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date hereof,
and Gossamer undertakes no obligation to update such statements to
reflect events that occur or circumstances that exist after the
date hereof. All forward-looking statements are qualified in their
entirety by this cautionary statement, which is made under the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201116005482/en/
For Investors and Media: Bryan Giraudo, Chief Financial
Officer Gossamer Bio Investor Relations ir@gossamerbio.com
Gossamer Bio (NASDAQ:GOSS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Gossamer Bio (NASDAQ:GOSS)
Historical Stock Chart
From Apr 2023 to Apr 2024